Biomea Fusion Ownership
| BMEA Stock | USD 7.24 0.22 3.13% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Biomea |
Biomea Stock Ownership Analysis
About 25.0% of the company shares are held by company insiders. The book value of Biomea Fusion was currently reported as 2.1. The company recorded a loss per share of 4.01. Biomea Fusion had not issued any dividends in recent years. Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The company was incorporated in 2017 and is headquartered in Redwood City, California. Biomea Fusion operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. For more info on Biomea Fusion please contact the company at 650 980 9099 or go to https://biomeafusion.com.Besides selling stocks to institutional investors, Biomea Fusion also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Biomea Fusion's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Biomea Fusion's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Biomea Fusion Quarterly Liabilities And Stockholders Equity |
|
Biomea Fusion Insider Trades History
About 25.0% of Biomea Fusion are currently held by insiders. Unlike Biomea Fusion's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Biomea Fusion's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Biomea Fusion's insider trades
Biomea Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biomea Fusion is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomea Fusion backward and forwards among themselves. Biomea Fusion's institutional investor refers to the entity that pools money to purchase Biomea Fusion's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 310.4 K | Two Sigma Investments Llc | 2024-09-30 | 273.9 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 244.7 K | Woodline Partners Lp | 2024-09-30 | 241.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 208.4 K | Rock Springs Capital Management Lp | 2024-09-30 | 181.1 K | Deutsche Bank Ag | 2024-06-30 | 178.2 K | Jane Street Group Llc | 2024-06-30 | 134.9 K | Wexford Capital Lp | 2024-09-30 | 130.3 K | Fmr Inc | 2024-09-30 | 5.4 M | Cormorant Asset Management, Llc | 2024-09-30 | 3.6 M |
Biomea Fusion Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomea Fusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomea Fusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomea Fusion insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biomea Fusion Outstanding Bonds
Biomea Fusion issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biomea Fusion uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biomea bonds can be classified according to their maturity, which is the date when Biomea Fusion has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Biomea Fusion Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 1st of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 2nd of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomea Fusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomea Fusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomea Fusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomea Fusion Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.01) | Return On Assets (0.56) | Return On Equity (1.05) |
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomea Fusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.